2023 - Research.com Medicine in Finland Leader Award
The scientist’s investigation covers issues in Pharmacology, Pharmacokinetics, Oral administration, Crossover study and Cmax. His Pharmacology study combines topics in areas such as CYP3A4, Gemfibrozil and Pravastatin. His Pharmacokinetics research integrates issues from Endocrinology, Repaglinide, Genotype and CYP2C8.
His studies in Oral administration integrate themes in fields like Hypnotic, Midazolam and Grapefruit juice. In his research on the topic of Cmax, Lovastatin Acid is strongly related with Lovastatin. His Simvastatin course of study focuses on Hydroxymethylglutaryl-CoA reductase and Enzyme inhibitor and Atorvastatin.
Pertti J. Neuvonen mostly deals with Pharmacology, Pharmacokinetics, Crossover study, Anesthesia and Oral administration. Pertti J. Neuvonen has researched Pharmacology in several fields, including CYP3A4, CYP2C8 and Gemfibrozil. His studies deal with areas such as Endocrinology, Repaglinide and Antibacterial agent as well as Pharmacokinetics.
His Repaglinide research includes elements of SLCO1B1 and Genotype. His work on Midazolam, Analgesic and Local anesthetic as part of general Anesthesia research is frequently linked to Oxycodone, bridging the gap between disciplines. His Oral administration research focuses on subjects like Hypnotic, which are linked to Sedative.
Pertti J. Neuvonen spends much of his time researching Pharmacology, Pharmacokinetics, Anesthesia, Crossover study and CYP2C8. His work carried out in the field of Pharmacology brings together such families of science as Metabolite, Clopidogrel and CYP3A4. His Pharmacokinetics study integrates concerns from other disciplines, such as Ketamine and Ticlopidine.
His research investigates the connection between Anesthesia and topics such as Adverse effect that intersect with issues in Heart rate. His study on Crossover study is intertwined with other disciplines of science such as Endocrinology, Internal medicine and Dose–response relationship. His research in CYP2C8 intersects with topics in Gemfibrozil and Repaglinide.
His scientific interests lie mostly in Pharmacology, Pharmacokinetics, Metabolite, CYP3A4 and CYP2C8. His Pharmacology study combines topics from a wide range of disciplines, such as Clopidogrel and Pharmacogenetics. He integrates several fields in his works, including Pharmacokinetics and Crossover study.
His study in Metabolite is interdisciplinary in nature, drawing from both Cytochrome P-450 CYP3A and In vivo. His CYP2C8 research incorporates themes from Gemfibrozil and Repaglinide. His work deals with themes such as SLCO1B1, Lovastatin, Genotype and HMG-CoA reductase, which intersect with Simvastatin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance
Pertti J. Neuvonen;Mikko Niemi;Janne T. Backman.
Clinical Pharmacology & Therapeutics (2006)
Pharmacokinetic interactions with rifampicin : clinical relevance.
Mikko Niemi;Janne T. Backman;Martin F. Fromm;Pertti J. Neuvonen.
Clinical Pharmacokinectics (2003)
Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake
Mikko Niemi;Marja K. Pasanen;Pertti J. Neuvonen.
Pharmacological Reviews (2011)
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
Pertti J. Neuvonen;Teemu Kantola;Kari T. Kivistö.
Clinical Pharmacology & Therapeutics (1998)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Marja K. Pasanen;Mikko Neuvonen;Pertti J. Neuvonen;Mikko Niemi.
Pharmacogenetics and Genomics (2015)
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Mikko Niemi;Elke Schaeffeler;Thomas Lang;Martin F Fromm.
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Marja K Pasanen;Hanna Fredrikson;Pertti J Neuvonen;Mikko Niemi.
Clinical Pharmacology & Therapeutics (2007)
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole
K. T. Olkkola;J. T. Backman;P. J. Neuvonen.
Clinical Pharmacology & Therapeutics (1994)
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Mikko Niemi;Mikko Niemi;Mikko Niemi;Janne T. Backman;Janne T. Backman;Janne T. Backman;Lauri I. Kajosaari;Lauri I. Kajosaari;Lauri I. Kajosaari;Julian B. Leathart;Julian B. Leathart;Julian B. Leathart.
Clinical Pharmacology & Therapeutics (2005)
Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.
Jari J. Lilja;Kari T. Kivistö;Pertti J. Neuvonen.
Clinical Pharmacology & Therapeutics (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: